



**AOXIN Q&M**

**AOXIN Q & M DENTAL GROUP LIMITED**  
(Company Registration Number: 201110784M)  
(Incorporated in the Republic of Singapore)

---

**REFUND OF  
EXCESS CLAIM OF COST OF MATERIAL FOR FY2024**

---

**1. INTRODUCTION**

The Board of Directors (the “**Board**” or the “**Directors**”) of Aoxin Q & M Dental Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) wishes to inform shareholders that the National Healthcare Security Administration 国家医疗保障局 (“**NHSA**”), a Chinese government agency that oversees, *inter alia*, the nation’s health insurance plan and centralised purchasing of drugs and medical supplies, has recently launched a nation-wide drive requiring hospitals and clinics to conduct a “self-review” and “self-correction” [自查自纠] exercise in relation to insurance claims under the government medical co-payment scheme. In this regard, NHSA has requested our two hospitals, namely Shenyang Aoxin Q & M Stomatology Hospital Co., Ltd. and Shenyang City Shenhe District No. 6 Hospital (Shenyang Aoxin Q & M Stomatology Hospital Co., Ltd. – Branch Hospital) (the “**Hospitals**”) to conduct a self-review to identify potential overclaim from NHSA of cost of material related to dental treatments under the governmental medical co-payment scheme for the financial year 2024 (“**FY2024**”).

Further to the self-review, NHSA and the Hospitals have concluded that there was an excess claim of cost of material from NHSA amounting in aggregate to approximately RMB3.7 million for FY2024, which the Hospitals are required to refund NHSA. As at the date of this announcement, the Hospitals are in the process of making the refund.

The above is expected to have a material impact on our Group’s financials in the first half of the current financial year (“**FY2025**”). Further details will be furnished in the Group’s half year results for FY2025.

**2. TRADE WITH CAUTION**

Shareholders and potential investors are advised to exercise caution when dealing in the Company’s securities. When in doubt, Shareholders and potential investors are advised to seek independent advice from their stockbrokers, bank managers, solicitors, accountants or other professional advisers.

**By Order of the Board**

Dr. Shao Yongxin  
Executive Director and Group Chief Executive Officer

22 June 2025



---

For more information, please contact:

**Financial Controller**

Loo Keat Choon

Tel: 6235 1188

Email: calvin@aoxin.sg

*This announcement has been reviewed by the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. (the "**Sponsor**"). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "**Exchange**") and the Exchange assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.*

*The contact person for the Sponsor is Ms Foo Jien Jieng, 16 Collyer Quay, #10-00 Collyer Quay Centre, Singapore 049318, sponsorship@ppcf.com.sg*